We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Share
  • Facebook
  • Twitter
  • Linked In
  • Google+
back top
New Diamond Partners for Upcoming Years

1300 members from 70 countries Join ICRS

News

Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market might still be underappreciated by investors after its recent run?

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

01/09/2017

CENTENNIAL, Colo., Jan. 19, 2016 /PRNewswire-USNewswire/ — AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, was awarded U.S. Patent Number 9,186,253, titled Cartilage mosaic compositions and methods, for its new cartilage repair allograft, ProChondrix® Cartilage Restoration Matrix.

AlloSource’s New Cartilage Repair Product, ProChondrix, Receives Patent

AlloSource’s New Cartilage Repair Product, ProChondrix, Receives Patent

20/01/2016